Skip to main content
. 2016 Mar 24;127(23):2879–2889. doi: 10.1182/blood-2015-11-680546

Figure 5.

Figure 5

Evaluation of NKG2DL expression in patients treated with DAC for 10 days. Expression analysis of NKG2DL by RT-PCR on AML blasts from patients treated with DAC. In DAC-treated patients, NKG2DL expression is significantly higher at the end of cycle 1 (day 28) compared with day 4 or day 11 of treatment. (A-E) Expression of ULBP-1, ULBP-2, ULBP-3, MICA, and MICB (*P = .0069, **P = .0016, ***P = .0101, n.s. P = .0547, ****P = .03). Upregulation of NKG2DL during DAC treatment was noted; expression of DNAM ligands (PVR and Nectin-2) was not observed.